null

null

null

null

null

null

null

null

Minimal debt; primarily equity-financed clinical-stage biotech with cash runway as key leverage metric, not debt ratios.

Negligible direct sensitivity; no significant floating-rate debt. Higher rates increase cost of future equity dilution rounds.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API sourcing from specialized European CMOs; 2) Regulatory approval bottlenecks in FDA/EMA jurisdictions for rare-disease compounds.

Revenue is near-zero pre-commercialization; no material sovereign currency devaluation exposure currently.

Operations primarily US/Israel; minimal FX revenue exposure until product commercialization; USD-denominated burn rate dominates.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or very few CMO/API suppliers for QRX003 and QRX004; substitution would require regulatory re-validation.

Clinical-stage pharma; no cloud-critical commercial operations yet; disruption would affect administrative functions only.

Licensing/royalty model anticipated post-approval; potential partnerships with larger pharma for commercialization.

Minimal API coupling risk; not a software business. CMO switching carries 12-24 month regulatory re-validation cost.

Low Howey risk; revenue model is pharmaceutical product sales/licensing, not investment contract or token-based scheme.

Very High

Limited GDPR/CCPA exposure; clinical trial data subject to FDA/ICH GCP standards; patient data handled via compliant CROs.

Low antitrust risk; small-cap rare-disease focus with no dominant market position; orphan drug designations typical.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently 0% recurring revenue; pre-revenue stage. Future model expected to be transactional product sales plus potential royalties.

Primary monetization via orphan drug product sales (QRX003/QRX004) post-FDA approval; potential out-licensing secondary vector.

Orphan drug pricing expected at $50K-$300K+ annually per patient; pricing power derived from rare-disease designation and limited alternatives.

High theoretical pricing power given orphan drug status and no approved competitors for Netherton syndrome target indication.

Specialty pharma gross margins targeted at 70-85% post-commercialization, contingent on CMO manufacturing cost structure.

No free-rider risk; prescription drug model requires ongoing physician authorization and payer reimbursement per patient.

Sublinear growth model; commercialization via partners or lean salesforce. R&D headcount does not scale with revenue.

Marginal cost of growth is low post-approval; manufacturing scales via CMO contracts without proportional internal headcount addition.

Not applicable; no franchise network.

At 10x scale, CAC remains manageable given rare-disease KOL-driven prescribing; patient advocacy and specialist networks are key channels.

No network effects present; pharmaceutical product adoption driven by clinical evidence, physician education, and payer coverage.

-77.5% Return on Assets (Negative equity)

High recession resistance; rare genetic disease treatment is non-discretionary for affected patients with limited therapeutic alternatives.

Dermatologists and rare-disease specialists treating Netherton syndrome and related ichthyosis patients.

Hospital systems, specialty pharmacies, and payers/insurers covering ultra-rare dermatological conditions.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated primarily to clinical trials and regulatory submissions; minimal legacy infrastructure. Future-state R&D focused capital deployment.

0001671502

QNRX